Enrollment Completed for Phase 2 Clinical Trial Evaluating VG081821AC for the Treatment of Parkinson's Disease
Vimgreen Pharmaceuticals completed enrollment for its Phase 2 trial of VG081821AC, an A2A receptor antagonist for early-to-mid stage Parkinson's disease, with 150 participants. The trial aims to assess VG081821's safety and efficacy as monotherapy, potentially offering a non-dopaminergic treatment option to avoid motor complications associated with long-term L-Dopa use.
Highlighted Terms
Related News
Enrollment Completed for Phase 2 Clinical Trial Evaluating VG081821AC for the Treatment of Parkinson's Disease
Vimgreen Pharmaceuticals completed enrollment for its Phase 2 trial of VG081821AC, an A2A receptor antagonist for early-to-mid stage Parkinson's disease, with 150 participants. The trial aims to assess VG081821's safety and efficacy as monotherapy, potentially offering a non-dopaminergic treatment option to avoid motor complications associated with long-term L-Dopa use.